Clinical Trials in Phoenix

Showing 13521-13540 of 16,646 trials

Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor

NCT02418858

Recently, there has been increasing interest in performing DBS under general anesthesia, where the stimulated targets are located anatomically (i.e. on MRI) rather than physiologically via microelectrode recordings and intra-operative test stimulation. This technology has been termed "asleep" DBS and is performed with the patient under general anesthesia. Intraoperative imaging is utilized to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery. Because stereotactic accuracy (and surgical safety) is the surgical endpoint, there is no need for the patient to be awake during the procedure.

Essential Tremor

St. Joseph's Hospital and Medical Center, PhoenixStarted Feb 2015

Phoenix, Arizona, United States

COMPLETEDPhase 2248 miles

PoC in Rheumatoid Arthritis With Methotrexate

NCT00605735

The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate

Rheumatoid Arthritis, NOS

Bristol-Myers Squibb121 participantsStarted Mar 2008

Palm Desert, California, United States • Santa Monica, California, United States • Las Vegas, Nevada, United States +25 more locations

Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor

PoC in Rheumatoid Arthritis With Methotrexate

Find Trials by Condition in Phoenix

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Ph IIA Study (SOC +/- NS5B)

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Phase II, 2nd Line Melanoma - RAND Monotherapy

Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

Burn Outcomes in Young Adult Burn Survivors

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer